Science‐Based Approach to Harmonize Contraception Recommendations in Clinical Trials and Pharmaceutical Labels

Author:

Bowman Christopher J.1ORCID,Becourt‐Lhote Nathalie2,Boulifard Virginie3,Cordts Rüdiger4,Corriol‐Rohou Solange5ORCID,Enright Brian6,Erkman Linda7,Harris Jayne8,Hartmann Andreas7,Hilpert Jan9,Kervyn Sophie10,Mattson Britta11,Morford LaRonda12,Muller Mireille13,Powell Marcy14,Sobol Zhanna11,Srinivasan Rajamuthu15,Stark Claudia16,Thompson Kary E.17ORCID,Turner Katie J.17,Barrow Paul18

Affiliation:

1. Worldwide Research, Development, and Medical Pfizer Inc Groton Connecticut USA

2. Nonclinical Safety, Translational Medicine Servier Gidy France

3. Ipsen Pharma Les Ulis France

4. Boehringer Ingelheim Pharma GmbH & Co. KG Biberach Germany

5. Global Regulatory Policy, R&D AstraZeneca Paris France

6. Preclinical Safety AbbVie Inc. North Chicago Illinois USA

7. Preclinical Safety Novartis Pharma Basel Switzerland

8. Clinical Pharmacology & Safety Sciences, R&D AstraZeneca Cambridge UK

9. Translational Medicine, Pharma Research and Early Development Bayer AG Berlin Germany

10. UCB Pharma Braine‐l'Alleud Belgium

11. Merck & Co., Inc. West Point Pennsylvania USA

12. Lilly Research Laboratories Indianapolis Indiana USA

13. Regulatory Policy Novartis Pharma Basel Switzerland

14. GlaxoSmithKline Research Triangle Park North Carolina USA

15. Sanofi Pasteur Marcy L’Etoile France

16. Preclinical Development, Pharma Research and Early Development Bayer AG Berlin Germany

17. Nonclinical Safety Janssen Pharmaceuticals Spring House Pennsylvania USA

18. Pharma Research and Early Development F. Hoffmann‐La Roche Ltd. Basel Switzerland

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Reference84 articles.

1. Global, regional, and subregional trends in unintended pregnancy and its outcomes from 1990 to 2014: estimates from a Bayesian hierarchical model

2. ICH.S2(R1) harmonised tripartite guideline. Guidance on genotoxicity testing and data interpretation for pharmaceuticals intended for human use (2011).

3. ICH.S5(R3) Guidance on detection of reproductive and developmental toxicity for human pharmaceuticals (2020).

4. ICH.M3(R2) Guidance on nonclinical safety studies for the conduct of human clinical trials and marketing authorization for pharmaceuticals (2009).

5. Evolving knowledge of the teratogenicity of medications in human pregnancy

Cited by 2 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3